MedPage Today: Revisiting Neoadjuvant Hormones for ER+ Breast Cancer
July 5, 2016
Neoadjuvant endocrine therapy for estrogen receptor (ER)-positive breast cancer achieved response rates similar to those obtained with combination chemotherapy but with less toxicity, pooled data from 20 studies showed. The findings have implications for a majority of women with newly diagnosed early breast cancer, most of which is ER-positive disease. Clinical experience in the adjuvant […]
